14.75
Korro Bio Inc (KRRO) 最新ニュース
Korro Bio appoints new Chief Scientific Officer By Investing.com - Investing.com South Africa
Korro Bio appoints new Chief Scientific Officer - Investing.com
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - Yahoo Finance
Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha
Korro Bio reappoints CFO, names new principal accounting officer By Investing.com - Investing.com Canada
Korro Bio CFO Returns from Medical Leave - TipRanks
Korro Bio reappoints CFO, names new principal accounting officer - Investing.com
Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO - MarketScreener
Research Analysts Set Expectations for Korro Bio Q1 Earnings - Defense World
Q1 Earnings Forecast for Korro Bio Issued By William Blair - Armenian Reporter
HC Wainwright Reiterates Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Q1 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Royal Bank of Canada Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price - Defense World
Korro Bio Reports 2024 Financial Results and Progress - TipRanks
H.C. Wainwright maintains Buy rating on Korro Bio stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy rating on Korro Bio stock - Investing.com
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth - Investing.com Australia
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth By Investing.com - Investing.com South Africa
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo Finance
RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk - Marketscreener.com
Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities - TipRanks
Korro Bio, Inc. SEC 10-K Report - TradingView
Korro Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Korro Bio Reports Clean Safety Data in AATD Drug Trial, Secures $163M Runway - StockTitan
Korro Bio (KRRO) Projected to Post Earnings on Tuesday - Defense World
FDA grants orphan drug status to Korro’s AATD treatment By Investing.com - Investing.com Australia
Korro Bio gets FDA Orphan Drug tag (KRRO:NASDAQ) - Seeking Alpha
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation - Marketscreener.com
FDA grants orphan drug status to Korro’s AATD treatment - Investing.com
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - The Manila Times
Breakthrough for Rare Disease: FDA Awards Special Status to Korro Bio's Novel RNA Treatment - StockTitan
Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
What Will Korro Bio Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World
KRRO stock touches 52-week low at $28.71 amid market challenges - Investing.com Nigeria
Korro Bio CFO takes medical leave, interim officers appointed - MSN
Korro Bio CFO takes medical leave, interim officers appointed By Investing.com - Investing.com Nigeria
Korro Bio Appoints Interim CFO Amid Medical Leave - TipRanks
Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting Officer -February 11, 2025 at 04:05 pm EST - Marketscreener.com
KRRO stock touches 52-week low at $29.8 amid yearly slump - Investing.com
AllianceBernstein L.P.'s Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World
Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Update - MarketBeat
大文字化:
|
ボリューム (24 時間):